Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation

Leukemia volume 16, pages 2259–2266 (2002)Cite this article

Abstract

We retrospectively analyzed the percentages and absolute numbers of T cells, natural killer (NK) cells and NK cell subsets in cryopreserved samples of either bone marrow or blood non-T cell-depleted allogeneic MHC-matched hematopoietic grafts. Using flow cytometry, we found higher numbers of NK cells in aphereses than in bone marrow collections. We further investigated the distribution of NK cell subsets, defined by the cell surface expression of MHC class I-specific receptors, in these allogeneic grafts. The distribution of NK cell subsets from the two different origins were similar, with the exception of the CD158a/h+ NK cell subset, whose size appeared to be smaller in bone marrow. The search for relations between the numbers of infused cells and post-transplantation events demonstrated that increasing numbers of infused T cells but not NK cells are related with decreased overall survival. Our study highlights the toxicity of infused T cells but not NK cells in allogeneic MHC-matched hematopoietic grafts. These data pave the way for further trials to investigate the effect of NK cell infusion in MHC-matched allogeneic transplantation, and in particular whether ex vivo NK cell expansion and activation may enhance the anti-tumoral effect of the procedure and decrease its morbidity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lerner KG, Glucksberg H, Buckner CD . Bone-marrow transplantation N Engl J Med 1975 292: 832–843 (part I) and 895–902 (part II)

    Article  CAS  Google Scholar 

  2. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED . Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia Blood 1989 73: 1720–1728

    CAS  PubMed  Google Scholar 

  3. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED . Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms N Engl J Med 1989 320: 828–834

    Article  CAS  Google Scholar 

  4. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle Blood 1996 87: 1196–1198

    CAS  PubMed  Google Scholar 

  5. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Petersen F, Niederwieser D . Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer Blood 1996 88: 1501–1508

    CAS  PubMed  Google Scholar 

  6. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ . Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation N Engl J Med 2000 343: 750–758

    Article  CAS  Google Scholar 

  7. Kernan NA . T-cell depletion for the prevention of graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic Stem Cell Transplantation Blackwell Science: Oxford 1999 186–196

    Google Scholar 

  8. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG . Transplantation of anergic histoincompatible bone marrow allografts N Engl J Med 1999 340: 1704–1714

    Article  CAS  Google Scholar 

  9. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D . Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis Lancet 1995 345: 1144–1146

    Article  CAS  Google Scholar 

  10. Drobyski WR, Majewski D, Hanson G . Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease Biol Blood Marrow Transplant 1999 5: 222–230

    Article  CAS  Google Scholar 

  11. Trinchieri G . Biology of natural killer cells Adv Immunol 1989 47: 187–376

    Article  CAS  Google Scholar 

  12. Bennett M . Biology and genetics of hybrid resistance Adv Immunol 1987 41: 333–445

    Article  CAS  Google Scholar 

  13. Murphy WJ, Longo DL . The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation Immunol Rev 1997 157: 167–176

    Article  CAS  Google Scholar 

  14. Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ . Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation J Clin Invest 1998 101: 1835–1842

    Article  CAS  Google Scholar 

  15. Koh CY, Welniak LA, Murphy WJ . Adoptive cellular immunotherapy: NK cells and bone marrow transplantation Histol Histopathol 2000 15: 1201–1210

    CAS  PubMed  Google Scholar 

  16. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L . Receptors for HLA class-I molecules in human natural killer cells Ann Rev Immunol 1996 14: 619–648

    Article  CAS  Google Scholar 

  17. Lanier L . On guard-activating NK cell receptors Nat Immunol 2001 2: 23–27

    Article  CAS  Google Scholar 

  18. Long EO . Regulation of immune responses through inhibitory receptors Ann Rev Immunol 1999 17: 875–904

    Article  CAS  Google Scholar 

  19. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L . Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis Ann Rev Immunol 2001 19: 197–223

    Article  CAS  Google Scholar 

  20. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ . ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor Immunity 2001 14: 123–133

    Article  CAS  Google Scholar 

  21. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L . Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin Eur J Immunol 2001 31: 1076–1086

    Article  CAS  Google Scholar 

  22. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A . Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells Nature 2001 409: 1055–1060

    Article  CAS  Google Scholar 

  23. Cambiaggi A, Verthuy C, Naquet P, Romagne F, Ferrier P, Biassoni R, Moretta A, Moretta L, Vivier E . Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor Proc Natl Acad Sci USA 1997 94: 8088–8092

    Article  CAS  Google Scholar 

  24. Koh CY, Blazar BR, George T, Welniak LA, Capitini CM, Raziuddin A, Murphy WJ, Bennett M . Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo Blood 2001 97: 3132–3137

    Article  CAS  Google Scholar 

  25. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A . Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation Blood 1999 94: 333–339

    CAS  PubMed  Google Scholar 

  26. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 2002 295: 2097–2100

    Article  CAS  Google Scholar 

  27. Karre K . Immunology. A perfect mismatch Science 2002 295: 2029–2031

    Article  CAS  Google Scholar 

  28. Zeis M, Uharek L, Glass B, Steinmann J, Dreger P, Gassmann W, Schmitz N . Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice Br J Haematol 1997 96: 757–761

    Article  CAS  Google Scholar 

  29. Cerwenka A, Baron JL, Lanier LL . Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo Proc Natl Acad Sci USA 2001 98: 11521–11526

    Article  CAS  Google Scholar 

  30. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH . Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity Nature 2001 413: 165–171

    Article  CAS  Google Scholar 

  31. Blaise D, Jourdan E, Michallet M, Jouet JP, Boiron JM, Michel G, Faucher C, Fegueux N, Schuller MP, Badri N, Chabannon C, Maraninchi D . Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study Bone Marrow Transplant 1998 22: 1153–1158

    Article  CAS  Google Scholar 

  32. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Boiron JM, Schuller MP, Moatti JP, Michallet M . Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle J Clin Oncol 2000 18: 537–546

    Article  CAS  Google Scholar 

  33. Olivero S, Alario T, Ladaique P, Haccoun M, Viens P, Blaise D, Chabannon C . CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol Bone Marrow Transplant 1999 23: 387–394

    Article  CAS  Google Scholar 

  34. Andre P, Biassoni R, Colonna M, Cosman D, Lanier LL, Long EO, Lopez-Botet M, Moretta A, Moretta L, Parham P, Trowsdale J, Vivier E, Wagtmann N, Wilson MJ . New nomenclature for MHC receptors Nat Immunol 2001 2: 661

    Article  CAS  Google Scholar 

  35. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringden O, Zander A, Apperley JF, Gorin C, Borkett K, Schwab G, Goebel M, Russell NH, Gratwohl A . Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 1998 21: 995–1003

    Article  CAS  Google Scholar 

  36. Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ, Lorand-Metze I, Oliveira GB, Correa ME, Reis AR, Miranda EC, de Souza CA . A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies Bone Marrow Transplant 1998 22: 1145–1151

    Article  CAS  Google Scholar 

  37. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, Shepherd V, Rowland A, Sirohi B, Tait D, Horton C, Long S, Singhal S . Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial Lancet 2000 355: 1231–1237

    Article  CAS  Google Scholar 

  38. Cooper MA, Fehniger TA, Caligiuri MA . The biology of human natural killer-cell subsets Trends Immunol 2001 22: 633–640

    Article  CAS  Google Scholar 

  39. Andre P, Spertini O, Guia S, Rihet P, Dignat-George F, Brailly H, Sampol J, Anderson PJ, Vivier E . Modification of P-selectin glycoprotein ligand-1 with a natural killer cell-restricted sulfated lactosamine creates an alternate ligand for L-selectin Proc Natl Acad Sci USA 2000 97: 3400–3405

    Article  CAS  Google Scholar 

  40. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de La Rubia J, Brunet S, Perez-Oteiza J, Ferra C, Zuazu J, Caballero D, Carvalhais A, Diez JL, Espigado I, Martinez C, Campilho F, Sanz MA, Sierra J, Garcia-Conde J, Montserrat E . The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings Blood 2001 97: 383–387

    Article  CAS  Google Scholar 

  41. Williams NS, Kubota A, Bennett M, Kumar V, Takei F . Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression Eur J Immunol 2000 30: 2074–2082

    Article  CAS  Google Scholar 

  42. Roth C, Carlyle JR, Takizawa H, Raulet DH . Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC Immunity 2000 13: 143–153

    Article  CAS  Google Scholar 

  43. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S . Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance Adv Immunol 2000 74: 181–273

    Article  CAS  Google Scholar 

  44. Maenaka K, Juji T, Nakayama T, Wyer JR, Gao GF, Maenaka T, Zaccai NR, Kikuchi A, Yabe T, Tokunaga K, Tadokoro K, Stuart DI, Jones EY, Van Der Merwe PA . Killer cell Immunoglobulin receptors and T cell receptors bind peptide- major histocompatibility complex class I with distinct Thermodynamic and kinetic properties J Biol Chem 1999 274: 28329–28334

    Article  CAS  Google Scholar 

  45. Liberatore C, Capanni M, Albi N, Volpi I, Urbani E, Ruggeri L, Mencarelli A, Grignani F, Velardi A . Natural killer cell-mediated lysis of autologous cells modified by gene therapy J Exp Med 1999 189: 1855–1862

    Article  CAS  Google Scholar 

  46. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T . Broad tumor-associated expression and recognition by tumor-derived gammadelta T cells of MICA and MICB Proc Natl Acad Sci USA 1999 96: 6879–6884

    Article  CAS  Google Scholar 

  47. Vivier E, Tomasello E, Paul P . Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol 2002 14: 306–311

    Article  CAS  Google Scholar 

  48. Lister J, Rybka WB, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL . Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period Clin Cancer Res 1995 1: 607–614

    CAS  PubMed  Google Scholar 

  49. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W, Whiteside T, Ball E . Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer J Immunother 2000 23: 154–160

    Article  CAS  Google Scholar 

  50. Pascal V, Vivier E, André P . CD158 (killer immunoglobulin-like receptors family) report In: Mason D, André P, Bensussan A, Buckley C, Civin C, Clark E, de Hass M, Goyert S, Hadam M, Hart D, Horejsi V, Jones Y, Meuer S, Morrissey J, Schwartz-Albiez R, Shaw S, Simmons D, Turni L, Uguccioni M, van der Schoot M, Vivier E, Zola H (eds) Leucocyte Typing VII. White Cell Differentiation Antigens Oxford University Press: Oxford 2002 pp 412–413

    Google Scholar 

Download references

Acknowledgements

The authors thank Pascale Paul (CIML) for helpful discussion, the Hematology Laboratory (Hopital de la Conception) and the Cell Therapy Facility (Institut Paoli-Calmettes) for support during the conduct of this work. This work was supported in part by institutional grants from INSERM, CNRS, Ministère de l'enseignement supérieur et de la Recherche, specific grants from Ligue Nationale contre le Cancer (Equipe labellisée La Ligue), from Association pour la Recherche contre le Cancer (EV, VP) and by Institut Paoli-Calmettes. The authors also thank the Beckman-Coulter Company for its contribution to the conduct of this work.

Author information

Authors and Affiliations

  1. Centre d'Immunologie INSERM/CNRS de Marseille-Luminy, Marseille, France

    V Pascal & E Vivier

  2. Laboratoire d'Hématologie, Hôpital de la Conception, Marseille, France

    V Pascal, C Brunet, J Sampol, F Dignat-George & E Vivier

  3. Institut Paoli-Calmettes, Centre Régional de Lutte Contre le Cancer Provence-Alpes-Côte d'Azur, Marseille, France

    C Faucher, D Blaise & C Chabannon

  4. Département d'Information Médicale, Hôpital de Sainte Marguerite, Marseille, France

    V Pradel & X Thirion

  5. Institut Universitaire de France,

    E Vivier

  6. Innate Pharma, Marseille, France

    P Andre

Authors
  1. V Pascal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Brunet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V Pradel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X Thirion
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Andre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Faucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Sampol
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Dignat-George
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Vivier
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Chabannon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pascal, V., Brunet, C., Pradel, V. et al. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogeneic hematopoietic transplantation. Leukemia 16, 2259–2266 (2002). https://doi.org/10.1038/sj.leu.2402670

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402670

Keywords

This article is cited by

Search

Advanced search

Quick links